Max Robotics — Global Service Robot Directory + US Certification

About

Boldizsar Kovacs is a leading figure in the emerging field of cardiac radioablation, where his work bridges radiation oncology and cardiology to treat life-threatening arrhythmias. His major contributions center on standardizing treatment planning for stereotactic ablative radiotherapy (SABR) targeting ventricular tachycardia, a condition with limited therapeutic options. Kovacs spearheaded the multicenter, multiplatform benchmarking study for the landmark RAdiosurgery for VENtricular TAchycardia (RAVENTA) trial, published in 2022. This work, already cited 12 times, established critical dosimetric benchmarks and inter-institutional consistency, directly enabling safer and more effective clinical implementation of this non-invasive procedure. By harmonizing planning protocols across diverse platforms and centers, Kovacs has addressed a key barrier to the widespread adoption of cardiac radioablation. His research not only demonstrates technical rigor but also holds profound translational impact, offering a new lifeline to patients with refractory ventricular arrhythmias. Through this pivotal study, Kovacs has positioned himself at the forefront of a rapidly evolving interdisciplinary frontier, shaping how radiation is precisely delivered to a moving target—the beating heart.